Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To obtain further information on the tolerability and efficacy of Atrovent® inhaletten® in the treatment of chronic obstructive airways disease under conditions of daily practice
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chronic Obstructive Airways Disease |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atrovent® Inhaletten | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Investigator assessment of improvement in the clinical picture of the course on a 6-point symptoms profile | Up to 4 weeks after first study drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Investigator assessment of tolerability on a 4-point scale | Up to 4 weeks after first study drug administration | |
| Investigator assessment of efficacy on a 4-point scale | Up to 4 weeks after first study drug administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhaletten®
Not provided
Not provided
Not provided
Patients with chronic obstructive airways disease recruited at general practitioners, pneumologists, internists
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of patients with adverse drug reactions | Up to 4 weeks after first study drug administration |
| Number of patients who withdrew from the study | Up to 4 weeks after first study drug administration |
| Number of patients who changed the concomitant medication | Up to 4 weeks after first study drug administration |
| Number of patients who continued treatment | Up to 4 weeks after first study drug administration |
| Patient assessment of tolerability on a 4-point scale | Up to 4 weeks after first study drug administration |
| Patient assessment of efficacy on a 4-point scale | Up to 4 weeks after first study drug administration |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |